United States Liquid Biopsy Growth Opportunities

United States Liquid Biopsy Growth Opportunities

Non-invasive Liquid Biopsy Technology Shapes the Precision Diagnostics Landscape

RELEASE DATE
22-Feb-2022
REGION
North America
Deliverable Type
Market Research
Research Code: K695-01-00-00-00
SKU: HC03509-NA-MT_26295
AvailableYesPDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03509-NA-MT_26295

$4,950.00

$3,712.50save 25 %

DownloadLink
ENQUIRE NOW

Description

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio.

Advances in next-generation sequencing-based companion diagnostics (CDx) and liquid biopsy (LBx) enable precision medicine approaches toward diseases such as cancer. Another aspect changing the diagnostics industry is linking automation to digital technologies to improve efficiency and productivity. This includes leveraging artificial intelligence to enhance workflow and accuracy.

Frost & Sullivan’s analysis shows that the top 5 companies in the US liquid biopsy market—Exact Sciences, Guardant Health, Roche/Foundation Medicine, Natera, and LabCorp—account for 77.5% of its revenue in 2020. We expect the market to reach $7.02 billion by 2025 at a 14% CAGR.

The report provides updates on the competitive landscape by analyzing market dynamics, participants, and investments. It also offers stakeholders insights through forecasts, analysis by therapy (oncology and non-oncology) and product type (kits and reagents, instruments and analysis platforms, testing and development services), and growth opportunities.

Author: Amol Dilip Jadhav

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the Liquid Biopsy Market

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Segmentation by Therapy

Segmentation by Product Type

Key Competitors by Product Type and Therapy

Terminologies

Major cfNA Analysis Methods are PCR- or NGS-based

Review of Liquid Biopsy Applications by Analytes in Cancer

cfNA Diagnostics Applications across the Cancer Care Continuum

Key Growth Metrics

Growth Drivers

Growth Restraints

Regulatory Landscape

Forecast Assumptions

Revenue Forecast

Revenue Forecast by Therapy

Revenue Forecast by Oncology Product/Service Type

Revenue Forecast by NIPT Product/Service Type

Revenue Forecast for Other Products/Services

Revenue Forecast Analysis

Revenue Forecast Analysis by Selected Products/Services

Revenue Forecast Analysis by Therapy

Competitive Environment

Revenue Share

Revenue Share—Oncology Therapy

Revenue Share—NIPT Therapy

Revenue Share Analysis

Key Growth Metrics

Revenue Forecast—Oncology Therapy

Revenue Forecast Analysis—Oncology Therapy

Key Growth Metrics

Revenue Forecast—Non-oncology Therapy

Revenue Forecast Analysis—Non-oncology Therapy

Competitive Ecosystem

Competitor Matrix

Competitor Matrix (continued)

Key Company Profiles

Key Company Profiles (continued)

Key Company Profiles (continued)

Key Company Product Matrix

Funding Trends

Mergers & Acquisitions and Partnerships

Mergers & Acquisitions and Partnerships (continued)

Growth Opportunity 1—Use AI-ML on Liquid Biopsy Data to Identify Novel Biomarkers

Growth Opportunity 1—Use AI-ML on Liquid Biopsy Data to Identify Novel Biomarkers (continued)

Growth Opportunity 2—Expand Liquid Biopsy NGS as CDx through Co-development Partnerships

Growth Opportunity 2—Expand Liquid Biopsy NGS as CDx through Co-development Partnerships (continued)

Growth Opportunity 3—cfDNA Methylation as a Pan-cancer Screening Biomarker

Growth Opportunity 3—cfDNA Methylation as a Pan-cancer Screening Biomarker (continued)

Growth Opportunity 4—Liquid Biopsy for Early Neurodegenerative Disease Detection

Growth Opportunity 4—Liquid Biopsy for Early Neurodegenerative Disease Detection (continued)

Growth Opportunity 5—Comprehensive Cancer Profiling to Improve Cancer Management for Hospitals and Laboratories

Growth Opportunity 5—Comprehensive Cancer Profiling to Improve Cancer Management for Hospitals and Laboratories (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnostics (CDx) and liquid biopsy (LBx) enable precision medicine approaches toward diseases such as cancer. Another aspect changing the diagnostics industry is linking automation to digital technologies to improve efficiency and productivity. This includes leveraging artificial intelligence to enhance workflow and accuracy. Frost & Sullivan’s analysis shows that the top 5 companies in the US liquid biopsy market—Exact Sciences, Guardant Health, Roche/Foundation Medicine, Natera, and LabCorp—account for 77.5% of its revenue in 2020. We expect the market to reach $7.02 billion by 2025 at a 14% CAGR. The report provides updates on the competitive landscape by analyzing market dynamics, participants, and investments. It also offers stakeholders insights through forecasts, analysis by therapy (oncology and non-oncology) and product type (kits and reagents, instruments and analysis platforms, testing and development services), and growth opportunities. Author: Amol Dilip Jadhav
More Information
Deliverable Type Market Research
No Index No
Podcast No
Author Amol Dilip Jadhav
Industries Healthcare
WIP Number K695-01-00-00-00
Keyword 1 liquid biopsy
Keyword 2 cancer biopsy
Keyword 3 LBx Market
Is Prebook No
GPS Codes 9600-B1,9562-B1,9568-B1,9611-B1,9627-B1